Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease. - Di Caro V; Cho E; Thiel J; Lizama BN; Koel-Simmelink MJA; Pandey K; Duong D; Seyfried NT; Grundman M; Teunissen CE; Zetterberg H; Blennow K; et al. (Alzheimer's research & therapy, 2026)